AMADEUS: Are New Stroke and Bleeding Risk Scores for AFib Patients Better Than Traditional Models?
Using data from the vitamin K antagonist arm of the AMADEUS Trial, investigators created two composite endpoints: stroke/thromboembolism plus major bleeding; and stroke, systemic or venous embolism, MI, cardiovascular death (CVD) or major bleeding. The endpoints were validated in a cohort of 441 AFib patients receiving antithrombotic therapy.
As a result of the findings, the study investigators suggest continued use of the CHADS2-VASc and HAS-BLED risk scores, which they say allow for greater practically for everyday clinical practice and more personalized balancing of risks. "Simplicity is best," said Gregory YH Lip, MD, FACC, professor of cardiovascular medicine at the University of Birmingham, UK. "Assess stroke using CHADS2-VASc and assess bleeding risk with HAS-BLED."
Clinical Topics: Heart Failure and Cardiomyopathies
Keywords: Vitamin K, Thromboembolism, Stroke, Ischemic Attack, Transient, Ventricular Dysfunction, Left, Hemorrhage
< Back to Listings